Genmab GMAB.CO
Genmab is a Danish biotechnology company that develops and commercializes therapeutic antibodies for the treatment of cancer, basing its business model on proprietary innovation and collaboration and licensing agreements with large pharmaceutical companies such as AbbVie. Genmab shows solid financial health (operating margin 35.24%, liquidity 2.46) and revenue growth of 24.9%, but the decline in profit (-9.4%) and demanding valuation (P/E 27.51, PEG 4.37) limit attractiveness; Phase III catalysts in Q4 are key.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Genmab is a Danish biotechnology company that develops and commercializes therapeutic antibodies for the treatment of cancer, basing its business model on proprietary innovation and collaboration and licensing agreements with large pharmaceutical companies such as AbbVie. Genmab shows solid financial health (operating margin 35.24%, liquidity 2.46) and revenue growth of 24.9%, but the decline in profit (-9.4%) and demanding valuation (P/E 27.51, PEG 4.37) limit attractiveness; Phase III catalysts in Q4 are key.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.3 |
| Quality / Moat | 7.1 |
| Valuation | 4.1 |
| Growth | 5.7 |
| Dividend | 1.5 |
| Momentum | 2.5 |
| Risk & Context | 7.4 |
OVERALL SCORE: 5.6/10
Context and risks
Inherent regulatory risk in the biotech sector: Phase III results and pending approvals (epcoritamab) are critical events. Additionally, dependence on collaborations with large pharma (AbbVie) concentrates execution risk.
News considered in the analysis
- Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 — Tres lecturas de Fase III en Q4 son eventos de alto impacto para el valor, con probabilidad de éxito moderada y parcialmente descontado por el mercado.
- Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline Risks — Recorte de valor razonable por riesgos de pipeline, refleja cautela de analistas, ya parcialmente en el precio.
- Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle? — Potencial de crecimiento de regalías, pero especulativo y no descontado.
- Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? — Prueba regulatoria para epcoritamab, relevante pero con probabilidad incierta.
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More — Listado genérico de llamadas de analistas, sin información nueva específica.
Verdict: Hold pending Phase III results; regulatory risk and high valuation do not justify aggressive entry.
Main risk: Dependence on Phase III trial outcomes and regulatory approval of epcoritamab, which could significantly impact the stock's value.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →